Revolution Medicines to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company, announced participation in two investor conferences. CEO Mark A. Goldsmith will present at the Oppenheimer 31^st Annual Healthcare Conference on March 16, 2021, from 1:10 to 1:40 p.m. Eastern. Additionally, he will participate in a fireside chat at the J.P. Morgan 10^th Annual Napa Valley Forum on March 29, 2021, from 2:00 to 2:45 p.m. Eastern. Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers, with R&D initiatives around RAS(ON) and Companion Inhibitors.

REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will deliver a corporate presentation at the Oppenheimer 31^st Annual Healthcare Conference and be the featured speaker in a fireside chat at the J.P. Morgan 10^th Annual Napa Valley Forum.

Details of these events are as follows:

• Oppenheimer 31^st Annual Healthcare Conference
  Conference Date: March 16-18, 2021
  Presentation Time/Date: 1:10 – 1:40 p.m. Eastern on Tuesday, March 16, 2021
  Format: Virtual conference
  

• J.P. Morgan 10^th Annual Napa Valley Forum
  Conference Date: March 29-31, 2021
  Fireside Chat Time/Date: 2:00 – 2:45 p.m. Eastern on Monday, March 29, 2021
  Format: Virtual conference

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

 

FAQ

What is the schedule for Revolution Medicines' presentations at the investor conferences in March 2021?

Revolution Medicines will present at the Oppenheimer 31^st Annual Healthcare Conference on March 16, 2021, from 1:10 to 1:40 p.m. Eastern, and at the J.P. Morgan 10^th Annual Napa Valley Forum on March 29, 2021, from 2:00 to 2:45 p.m. Eastern.

Who will represent Revolution Medicines at the upcoming investor conferences?

Mark A. Goldsmith, M.D., Ph.D., the CEO and chairman of Revolution Medicines, will represent the company at both conferences.

What topics will Revolution Medicines cover during the investor conferences?

Revolution Medicines will discuss their development of targeted therapies for RAS-addicted cancers, including RAS(ON) and Companion Inhibitors.

Is the Oppenheimer conference in-person or virtual?

The Oppenheimer 31^st Annual Healthcare Conference is a virtual conference.

What are RAS(ON) Inhibitors?

RAS(ON) Inhibitors are drugs developed by Revolution Medicines designed to suppress various oncogenic variants of RAS proteins.